Biocon on Monday said it received zero observations for its active pharmaceutical ingredient (API) plant in Visakhapatnam, Andhra Pradesh.
The plant was inspected from September 11-15, 2017.
“The successful audit of this facility reflects our strong commitment to cGMP compliance at our manufacturing facilities,” Biocon said in a statement.
Biocon has acquired the manufacturing unit from Acacia Lifesciences in October 2015.
The unit manufactures advanced intermediates of active pharma ingredients (APIs) useful in vertically integrating oncology-related abbreviated new drug application (ANDA) filings of Biocon in the future and for supply to third-party customers.
Shares of Biocon rose 2.94 percent to close at Rs 357.05 on BSE, the benchmark Sensex gained 0.47 percent to end at 32,423.76 points.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
